Survival and maturation of mDCs in the presence of IMiDs. Human blood myeloid dendritic cells (mDCs) were incubated for 24 hours with lipopolysaccharide (LPS) (A-B) or thymic stromal lymphopoietin (TSLP) (A,C-D) and the different concentrations of lenalidomide (LEN), pomalidomide (POM), or bortezomib (BOR) (A,D: LEN or POM were used at 1 μM). After culture, viable cells were evaluated by Annexin-V staining. Before and after the culture, the expressions of CD86, CD80, CD83, and OX40L on mDCs was analyzed by flow cytometry. (A) Each histogram shows the expression of the indicated markers on mDCs freshly isolated or stimulated with LPS/TSLP alone or LPS/TSLP + 1 μM LEN for 24 (CD86, CD80, and CD83) or 48 hours (OX40L). Similar results were observed in at least 4 independent experiments and the results of a representative experiment are shown. (B-D) Data indicate the mean fluorescence intensity (MFI), calculated by subtracting the MFI of the isotype control-treated cells from the MFI of the cells treated with the indicated monoclonal antibodies. Each experiment was performed using DCs from a single donor, and data are shown as the mean ± SEM of 6 independent donors (cell viability and CD86) and 4 independent donors (CD80, CD83, and OX40L). Statistical significance was determined using a paired Student t test (**P < .01). Comparisons between data obtained for vehicle controls (indicated as LPS alone or TSLP alone) and for each concentration of the indicated drugs.